OncoMatch/Clinical Trials/NCT07276373
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Is NCT07276373 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Nenocorilant 200 mg and Nenocorilant 300 mg for neoplasms.
Treatment: Nenocorilant 200 mg · Nenocorilant 300 mg · Nenocorilant 400 mg · Nivolumab — This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Cardiac function
QTcF interval >450 msec, family history of long QT syndrome or unexplained sudden death at young age, or requirement for use of medication that may prolong the QTc interval [excluded]
Has adequate organ function; QTcF interval >450 msec, a family history of long QT syndrome or unexplained sudden death at young age, or a requirement for use of medication that may prolong the QTc interval
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Site 03 · Los Angeles, California
- Site 01 · San Antonio, Texas
- Site 02 · West Valley City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify